Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Formycon AGWBO:FYB +0.22%39 Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus rates WBO:FYB with a GF Score™ of 39/100 and a GF Value™ of €37.04 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Formycon AG ranks worse than 99.42% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Formycon AG's annualized net income for the quarter that ended in Dec. 2025 was €-21.01 Mil. Formycon AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €-31.35 Mil. Therefore, Formycon AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Formycon AG's Return-on-Tangible-Equity or its related term are showing as below:
WBO:FYB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4567.31 Med: -11.69 Max: 24.84
Current: -4567.31
During the past 13 years, Formycon AG's highest Return-on-Tangible-Equity was 24.84%. The lowest was -4,567.31%. And the median was -11.69%.
WBO:FYB's Return-on-Tangible-Equity is ranked worse than 99.42% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs WBO:FYB: -4567.31
Formycon AG (WBO:FYB) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Formycon AG Return-on-Tangible-Equity Related Terms
Formycon AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Formycon AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:FYB vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Formycon AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Formycon AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Formycon AG (WBO:FYB) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Formycon AG and its competitors. According to the industry distribution chart, Formycon AG ranks #1192 out of 1199 companies in the Biotechnology industry, placing it in the top 99.4%.
Is Formycon AG's Return-on-Tangible-Equity too high?
Formycon AG's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Formycon AG ranks #1192 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Formycon AG has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #1192 out of 1199 companies for Return-on-Tangible-Equity. This places Formycon AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Formycon AG and its competitors. Formycon AG's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (WBO:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €37.04, compared to a current price of €18.30 — trading 50.6% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Formycon AG's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Formycon AG (WBO:FYB), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (WBO:FYB) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €18.30 is trading 50.6% below its estimated GF Value™ of €37.04.
GuruFocus considers Formycon AG to be Possible Value Trap.
Key valuation signals for WBO:FYB:
Return-on-Tangible-Equity: 0.00%
GF Value™: €37.04 vs. price of €18.30 (50.6% below fair value)
No single metric tells the full story. See the WBO:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
39GF Score
Get the complete analysis for WBO:FYB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:FYB has been successfully added to your 
